(1888PressRelease)
April 20, 2008 - Dr. Urban Kiernan, Senior Research Scientist, Intrinsic Bioprobes will be speaking at GTCbio’s 2nd Annual Rediscovering Biomarkers Conference on July 10-11, 2008 in Boston, MA. Dr. Kiernan will present on affinity mass spectrometry in biomarkers.
The field of proteomics has extended its scope beyond basic research and is now attempting to enter clinical application and diagnostics. Historically, protein biomarker screening has been reserved for classical immunoassay methodologies, but recent developments in proteomic approaches have shown potential in this arena. Now possible with the recent development of novel proteomic devices and methodologies now allow for the high content analysis of clinically relevant proteins directly from human plasma. This novel approach to proteomics is a hybrid of immuno-affinity protein capture with MALDI-TOF MS detection.
The resulting mass spectrometry based immuno-assay platform was developed to perform top-down high throughput absolute or semi-quantitative measurements. It also has the capacity for qualitative differentiation, a novel feature not readily achievable with most classical immunoassay methodologies. This ability to discriminate between different forms of the same target protein allows for routine monitoring of posttranslational modifications (PTM) and point mutations (PM), which are observed as mass shifts from the wild-type protein signal. This presentation will describe how this novel top-down proteomic approach can be applied to rediscover old biomarkers and increase their clinical utility. Specific examples will be provided as to how this approach can be used in the improved assessment of myocardial infarction, cancer and type 2 diabetes.
The 2nd Annual Rediscovering Biomarkers Conference will expose attendees to the latest advancements and developments in biomarkers and predictive medicine. Attendees will gain insight into discovery and development processes, hear about new biomarkers and upcoming trends in the industry, as well as the status of those in clinical trials. Delegates will also receive highly valuable information on tools for improving reimbursement strategies and the efficacy and validation of biomarkers.
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=124
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio ( @ ) gtcbio dot com
